Skip to Main Content Menu Search Site

Wyss DxA Industrial Participant Program

A collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem, driven by the Wyss Diagnostics Accelerator

Want to join the Wyss DxA IPP?

We are currently seeking new members to join the pilot phase of the Wyss Diagnostics Accelerator Industrial Participant Program. Please get in touch to learn more.

Wyss DxA IPP Contacts

Head of Operations and Outreach
Trey Toombs, Program Director, Brigham Research Institute, Brigham and Women’s Hospital

Program Development
Gretchen Fougere, Business Development Manager, Wyss Institute

Wyss IPP Advisory Team
Elliot P. Cowan, David Levine, Jim Niemi, Richard Novak, Mac Strafford

Developing a new diagnostic that tests well in the lab is not enough – these tools need to work well at scale and in the market.

The Industrial Participant Program (IPP) is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem, driven by the Wyss Diagnostics Accelerator (DxA). Members of the IPP share the common goal of fast-tracking diagnostic technologies to meet unmet, critical needs. Credit: Wyss Institute at Harvard University

The Wyss Diagnostics Accelerator Industrial Participant Program (Wyss DxA IPP) serves as a collaboration hub between healthcare testing companies, and the scientific and clinical community within the Wyss Institute, as well as our affiliated institutions and the broader Harvard ecosystem.

Partners build relationships and explore pre-competitive collaboration opportunities, connect with thought leaders and subject matter experts, identify key opportunities and challenges within the industry, and align on a vision to transform the future of diagnostic and healthcare testing, all driven by the passion to solve unmet diagnostic needs.

The Industrial Participant Program (IPP) is the industry-facing component of the Wyss Diagnostics Accelerator. Learn more about our current program participants below.

Industrial Participants

Wyss DxA Industrial Participant ProgramBioDot
BioDot specializes in low volume fluid dispensing systems (picoliters to microliters) for product development and manufacturing in the diagnostic and life sciences industries. Every Drop Has A Story.

Contact: Debbie Bowers, Senior VP of Commercial Development, debbie.bowers@biodot.com

Wyss DxA Industrial Participant ProgrambioMérieux
In 160 countries, bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety.

Contact: Mahala Burn, PhD, Corporate Development and Strategic Financing, mahala.burn@biomerieux.com

Wyss DxA Industrial Participant ProgramCanatu
Canatu is a Finnish deep technology company that manufactures advanced carbon nanotubes (CNTs), related products, and equipment for the semiconductor, automotive, and medical diagnostics industries.

Contact: Nedal Safwat, Chief Development Officer and President, nedal.safwat@canatu.com

Wyss DxA Industrial Participant ProgramCountable Labs
Countable Labs (formerly Enumerix) is redefining PCR with single-molecule precision and category-defining sensitivity, overcoming the limitations of other PCR and next-generation sequencing approaches.

Contact: Anjali Pradhan, Chief Business Officer, apradhan@countablelabs.com

Wyss DxA Industrial Participant ProgramDiagMetrics
DiagMetrics is a development stage company focusing on using Exhaled Breath Condensate for rapid PoC and high-volume testing for infectious viral and bacterial diseases and other conditions. The Company’s current focus is on screening and confirmatory tests for TB, which infects over a quarter of the global population.

Contact: John Daniels, CEO & Co-Founder, john@diagmetrics.com

Wyss DxA Industrial Participant ProgramExOcular
ExOcular is developing a blood-based diagnostic test using biomarkers called exosomes for the early diagnosis and monitoring of severe eye diseases.

Contact: Lisa Padilla, CEO, lisa@exoculardx.com

Wyss DxA Industrial Participant ProgramGLX Analytix
At GLX Analytix, we combine a new, proprietary class of biomarker with AI to bring personalized medicine to your healthcare.

Contact: Brian Della Valle, Founder and CEO, brian@glxanalytix.com

Wyss DxA Industrial Participant ProgramIDEXX Laboratories, Inc.
Enhancing the health and well-being of pets, people, and livestock.

Contact: Ryan Cole, Director of Corporate Development & Strategy, ryan-cole@idexx.com

OLYMPUS DIGITAL CAMERAKephera Diagnostics
Kephera Diagnostics is developing new, affordable point-of-care diagnostic tests for emerging infectious diseases on its mobile platform.

Contact: Andrew Levin, President and Scientific Director, alevin@kephera.com

Wyss DxA Industrial Participant ProgramLabcorp
Labcorp is a global life sciences company that provides diagnostic testing and drug development services.

Contact: Stanley Letovsky Ph.D., Vice-President for AI, Data Sciences and Bioinformatics, letovss@labcorp.com

Wyss DxA Industrial Participant ProgramMilliporeSigma
From research to commercialization, MilliporeSigma provides a broad range of over 300,000 high-quality products and services, including supply chain solutions, packaging capabilities, technical support, e-commerce solutions, and more to help create solutions for your end-to-end needs.

Contact: Dianna Shields, Account Manager, dianna.shields@milliporesigma.com

Wyss DxA Industrial Participant ProgramNovartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

Contact: Chad Bigelow, Director, chad.bigelow@novartis.com

Wyss DxA Industrial Participant ProgramRomix Biosciences
Romix is developing a cell-free RNA platform, combining custom laboratory methods and AI/ML, to decode disease biology across the body, with an initial focus on predicting response to cellular therapy.

Contact: Conor Loy, CEO & Co-Founder, innovation@romixbio.com

Wyss DxA Industrial Participant ProgramSarmal
Enhancing healthcare efficiency through accessible and actionable genomics.

Contact: Inanc Ortac, Founder and CEO, iortac@sarmal.com

Wyss DxA Industrial Participant ProgramSeeQ Diagnostics
SeeQ diagnostics is brining rapid fully agnostic metagenomics into the clinical setting by offering a turn-key onsite solution to detect any DNA based pathogen from as little as 0.5 mL of whole blood in 6-8 hours. We are currently conducting prospective clinical studies across patient indications, with a primary focus on oncology/hematlogy, neonates and cardiovascular infections.

Contact: Anders B. Sørensen, CEO and Co-Founder, abs@seeqdx.com

Wyss DxA Industrial Participant ProgramSigenex
Clinical genetics for everyone everywhere.

Contact: Tan Rasab, Co-Founder and CEO, info@sigenex.com

Wyss DxA Industrial Participant ProgramQYN Labs
Building the first platform for real-time hormone sensing to power the next generation of AI-enabled healthcare that’s personalized, proactive, and data-driven.

Contact: Shilpi Gupta, Founder, shilpi@qynlabs.com/a>

Wyss DxA Industrial Participant ProgramWest Pharmaceutical Services
West Pharmaceutical Services is the leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines. We are a trusted partner to the world’s top pharmaceutical and biotechnology companies–working by their side to improve patient health.

Contact: Scott Young, VP Venture & External Collaboration, scott.young@westpharma.com

Wyss DxA Industrial Participant ProgramXylexa
At Xylexa, we envision a future where advanced AI and Cloud solutions seamlessly integrate with radiology practice, setting new standards of accuracy, efficiency, and accessibility in medical imaging diagnosis worldwide.

Contact: Shahid Abbasi, CEO, shahid.abbasi@xylexa.com

Wyss DxA Industrial Participant ProgramZoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals.

Contact: Stephane Shu Kin So, Director of Research Alliances and External Innovation, stephane.shukinso@zoetis.com

Program Leads

Wyss DxA Industrial Participant ProgramTrey Toombs is the Head of Operations and Outreach for the Wyss DxA Industrial Participant Program, applying his program management experience to help develop, launch and operationalize this new endeavor and facilitate collaborations that will accelerate the advancement of diagnostics. Trey also serves as a Program Director for the Brigham Research Institute, where he works closely with faculty and institutional leaders to create and execute initiatives to foster new interdisciplinary and interdepartmental research and raise the visibility of the broader research enterprise. Previously, Trey was a research fellow at Massachusetts General Hospital, received his Ph.D. in biochemistry and molecular biology from Colorado State University and his B.S. from Virginia Tech. Contact: james.toombs@wyss.harvard.edu

Wyss DxA Industrial Participant ProgramGretchen Fougere has a passion for and a track-record of building bridges between the academic and industrial worlds to solve problems. In academia for a decade, she led the development of strategy and programs that she launched, funded, and scaled globally, as well as raised millions for faculty research. Most recently, she was a leader in an innovation institute using AI and ML to advance computational medicine translation and life science discovery, and she raised millions for faculty in this startup. In industry for a decade, she focused on new product development as an inventor, innovator, and leader of cross-functional teams. At the Wyss, Gretchen works closely with faculty and research teams to build bridges with industry to translate cutting-edge ideas into new products, such as medical devices and diagnostics. She earned her Ph.D. in Materials Science/Nanotechnology from Northwestern University and two bachelor’s degrees in Mechanical Engineering and Biomedical Engineering from Vanderbilt University. Contact: gretchen.fougere@wyss.harvard.edu

Advisory Team

Members of the Wyss DxA IPP Advisory Team bring their broad experiences and diverse backgrounds to help guide and grow the program to benefit its participants.

Wyss DxA Industrial Participant ProgramElliot P. Cowan, Ph.D., is Principal and Founder, in 2013, of Partners in Diagnostics, LLC, providing consulting on the regulation of in vitro diagnostics to IVD manufacturers, and is the Chief Regulatory Officer of TestZone, dedicated to making spaces safer in the midst of pandemics. This followed a 20-year career at the US Food and Drug Administration, where he led the regulation of all blood donor screening tests and retroviral diagnostics. Elliot was also a member of the Laboratory Technical Working Group for the President’s Emergency Plan for AIDS Relief (PEPFAR), providing technical assistance for laboratory quality assurance issues in PEPFAR focus countries, advised the World Health Organization on the development of its Prequalification of Diagnostics Programme, and assisted in building regulatory systems for diagnostics in Sub-Saharan Africa. Elliot received a B.A. from Williams College and a Ph.D. in Biology and Biomedical Sciences from Washington University in St. Louis.

Wyss DxA Industrial Participant ProgramDavid Levine, M.D., M.P.H., M.A., is a practicing general internist and clinician-investigator at Brigham Health and Harvard Medical School. He is active in clinical and translational research through a focus on optimizing quality time at home by shifting care home, decentralizing care, digital health technology, and measuring the quality and experience of health care. He is medical director for strategy and innovation for the Brigham Health Home Hospital and co-chair of the Hospital at Home Users Group. He sees his role as helping patients achieve the right care at the right time in the right place by designing, implementing, and evaluating innovative interaction spaces among a care team, technology, caregiver, and a patient. David received his undergraduate degree from Pomona College in biology and politics. He earned his master’s in teaching in special and secondary science education and served as a high school chemistry teacher and science department chair in Chicago Public Schools. He received his medical degree from Washington University in St Louis and completed his residency at New York University and Bellevue Hospital in internal medicine – primary care. He completed a general internal medicine fellowship at Brigham Health and Harvard Medical School and received his master’s in public health at the Harvard School of Public Health.

Wyss DxA Industrial Participant ProgramJim Niemi has over 25 years of experience in medical device research, development, and commercialization. His prior interests and experience include neuromuscular stimulation and control, stochastic resonance for human neuromotor applications, advanced medical imaging, implantable smart sensors and materials, as well as bioreactor and automation design. Jim is currently the Lead Staff Engineer for the Living Cellular Devices focus area of the Wyss Institute focusing on applications of synthetic biology, in conjunction with traditional devices, for primarily diagnostic applications. Jim received his B.S. in Biomedical Engineering from Boston University and his M.S. in BioEngineering from Brown University. Contact: james.niemi@wyss.harvard.edu

Wyss DxA Industrial Participant ProgramRichard Novak, Ph.D., is the founding CEO of Unravel Biosciences, Inc., which he spun out from the Wyss Institute at Harvard University to develop therapeutics for orphan CNS diseases using a novel AI drug prediction and in vivo screening platform. Prior to Unravel Bio, he was a Lead Engineer at the Wyss Institute at Harvard University where he managed the Microengineering Team and led development of human Organ Chips, Organism-on-Chip screening platforms, and analytical and diagnostic instrumentation for accelerating therapeutics discovery and precision diagnostics. Richard received his PhD in Bioengineering from UC Berkeley/UC San Francisco where he developed microfluidic single cell analytical and diagnostic platforms for forensic, therapeutic, and basic research applications. He is the founder of Future Scientist, a nonprofit that works with resource-poor communities to design sustainable solutions through their prototyping and development hub in Panama. Richard also is a founder and director of Rhinostics Inc., a medical consumables company that has developed an automatable sample collection platform that accelerates and expands access to respiratory, blood, and genomic laboratory testing through integration with existing lab automation instruments.

Wyss DxA Industrial Participant ProgramMac Strafford is a healthcare professional with a background in management consulting. She currently oversees population health projects at Optum and previously served as a consultant at Bain & Company in the private equity practice. Throughout 2020, Mac also led Testing & Therapeutic efforts at a COVID-19 relief nonprofit called Stop the Spread. In this role, Mac supported over 100 diagnostic companies by connecting them with resources to accelerate their development timeline and enable greater scale.

Close menu